The FDA approved a once-daily, long-term olodaterol inhalation spray to treat patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema with airflow obstruction.
The FDA is mandating that manufacturers include a general warning on the drug labeling of all approved testosterone products to advise of the risk of blood clots.